Years Experience Design
Resume:
Personal Profile
Name: Pinglang Wang Email: ********@*******.***
Phone: 617-***-**** Location: US-MA-Cambridge-02140 (Citizen)
Experience
Total years experience: 20 Years Job Categories: Pharmaceutical (13
Years experience)
Work History
Job Title: Director of Chemistry (Sept. 2009 - May 2010)
Company Name: Pharmaadvance, Inc.
Job Title: Senior Synthetic / Medicinal Chemist (11 Years) February 1998 -
January 2009
Company Name: Organix, Inc
Job Title: Postdoctoral Research Associate (2 Years) August 1996 -
February 1998
Company Name: Department of Chemistry, Purdue University
Job Title: Research Associate (4 Years) February 1992 - August 1996
Company Name: Department of Agricultural and Biological Engineering, Purdue
University
Job Title: Research Associate (3 Years) August 1989 - February 1992
Company Name: Department of Medicinal Chemistry and Pharmacognosy, School of
Pharmacy and Pharmacogcy Science
Job Title: Postdoctoral Associate (1 Years) April 1988 - August 1989
Company Name: Department of Food Science, Purdue University
Education
School: Purdue University Major: Chemistry Degree: Registered as a no degree
student Graduation Date: February 1998
School: South China University of Technology Major: Carbohydrate Chemistry and
Technology Degree: Doctorate Graduation Date: December 1987
School: South China University of Technology Major: Carbohydrate Chemistry and
Technology Degree: Master Graduation Date: August 1985
School: Qiqihar Institute of Technology Major: Chemistry and Technology
Degree: Bachelor's Degree Graduation Date: January 1982
Additional Skills And Qualifications
Recent Job Title: Director of Chemistry, Senior Synthetic / Medicinal Chemist
Recent Wage: 85,000 USD per year
Managed Others: Yes (10 others) Languages Spoken: English
Security Clearance: No
Felony Conviction: No
Desired Position
Desired Wage: 85,000 USD per year Desired Employment Type: Full-Time
Desired Travel: Up to 25% Desired Commute: 50 miles
Desired Relocation: Yes
RESUME
Name : Pinglang Wang
Home address : 11 Cogswell Avenue, Apt. 12, Cambridge, MA 02140
Phone : 617-***-****
E-Mail : ********@*******.***
Visa status : US citizen
EDUCATION
April 1988 – February 1998:
After getting my Ph.D. I was further educated for ten years as a Postdoctoral Research
Associate at Purdue University by participating in course studies (I was registered as a no-
degree grad. student finished 44 credit hours with an 3.4/4.0 GPA) in the Departments of
Chemistry, Biochemistry, and Biology aiming at achieving a comprehensive knowledge of
structure-based design and synthesis of bioactive small molecules. Please see "Working
Experience" part and “Academic Transcript at Purdue University” for details. I can send the
Transcript if you like to see.
September 1982 – December 1987:
M.S. and Ph. D. from South China University of Technology (Guangzhou, China) in the field of
Carbohydrate Chemistry and Technology.
March 1978 – January 1982:
B.S. from Qiqihar Institute of Technology (Qiqihar, China) in Sugar Chemistry and Technology.
WORKING EXPERIENCE
September 2009 – May 2010:
Pharmaadvance, Inc. Jiangyin, China. I was Director of Chemistry in the company. I supervised
10 Ph.D. and M.S. chemists for organic synthesis on lead optimization projects. I evaluated and
carried out the synthesis routes the clients proposed, modified and redesigned the routes when
necessary, proposed/suggested new structures and their syntheses for the lead optimization,
distributed resources on each target compound synthesis, teached and trained chemists,
monitored research progress, solved problems encountered in practical synthesis, wrote weekly
updated reports, communicated with clients and delivered compounds requested on time.
February 1998 – January 2009:
Organix, Inc., 240 Salem Street, Woburn, MA 01801 . I was a Senior Scientist, Synthetic
Organic / Medicinal Chemist, prepared heterocyclic drug-like small molecules on the anti-cancer
and anti-inflammation projects for the major pharmaceutical companies in the USA .
August 1996 – February 1998:
Department of Chemistry, Purdue University, West Lafayette, IN 47907 . I was a Postdoctoral
Research Associate working for Professor Herbert C. Brown ( Nobel Prize winner in Chemistry in
1979) in the program of "Asymmetric Synthesis via Chiral Organoboranes". I synthesized and
characterized the chiral organoboranes, such as B-halo-2- and -4-isocaranylboranes for
asymmetric hydroboration of prochiral olefins ( I orally presented the results at 30th ACS
meeting); and 2-aryl-isopinocampheldichloroboranes used for asymmetric Diels-Alder reactions,
etc.
February 1992 – August 1996:
Department of Agricultural and Biological Engineering, Purdue University. I was a Research
Associate working for Professor Bernard Tao. The research included design and synthesis of
biodegradable materials, analyzed the structures by NMR, IR, and Mass spec., etc. During this
period of time, while doing research, I also took courses: (a) Organometallic Chemistry; (b)
Computational Organic Chemistry; (c) Advanced Organic Chemistry; (d) NMR Spectroscopy; (e)
Synthetic Organic Chemistry; (f) Protein-Protein Interactions; (g) General Biochemistry; (h)
Structure and Function of Proteins; (i) Structure and Function of Nucleic Acids; (j) Molecular
Virology; (k) Immunobiology. They are so good for a medicinal chemist to design and synthesize
promising small molecules based on the bio-target structures. I got all "A" grades for the courses
(a), (c), and (e), those are the most important for a synthetic organic chemist.
August 1989 – February 1992:
Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacogcy
Science, Purdue University . I was a Research Associate working for Professor Mark Cushman.
My research included synthesis, separation, characterization and chemical structure
determination of the ATA (aurintricarboxylic acid) molecules which are anti-HIV active. The fruitful
work resulted in four publications, one is in J. Med. Chem., two in J. Org. Chem., and one in
Antiviral Chem. & Chemotherapy. I also participated in the course studies: "Chemistry of High
Polymer", and "Organic Chemistry". Both were on "A" grades.
April 1988 – August 1992:
Department of Food Science, Purdue University . Postdoctoral Associate working for Professor
Roy L. Whistler. The research was isolation and chemical/enzymatic modification of
hemicelluloses.
SCIENTIFIC AND TECHNICAL SKILLS
I am an educated and experienced synthetic organic/medicinal chemist. I am especially
expertised in designing and synthesizing heterocyclic, drug-like small molecules based on target
protein structures (TPS) or pharmacophores (if TPS is not known) from the known active
molecules to a disease.
I have designed and synthesized dozens of heterocyclic small molecules in the past years as a
Director of Chemistry or a Senior Scientist. Those molecules: (a) either use a single heterocycle
as a core directly connected with two or three other heterocyclic moieties which further attached
functional groups (-F, Cl, H2NCONH-, CH2CONOH, depending on H-bonding, hydrophobic,
or ionic interactions with binding sites needed for complementary fitness. (b) or use a fused
heterocycle as a core ….. The heterocycles include isoxazole, thiophene, hydantoin, imidazole,
pyrazole, triazole, oxadiazole, pyridazine, quinoline, quinazoline. I collected and often review the
published drug synthesis for pain and inflammation managements, inhibiting cancer cell growth,
treatment of cardiovascular disease, diabetes treatment, stress-related disease
(anxiety/depression), mental retardation from Pfizer, Merck, GlaxoSmithKline, Wyeth, Bristol-
Myers Squibb, Merrel Dow, Parker-Davis, Waner-Lambert, Shinogi, Ortho, Pennwall, SRI, IBI
SUD, Eli Lilly, Upjohn, Teva, N.V. Janssen, Hoechst totally 528 schemes. All these are
beautiful heterocyclic small molecule syntheses. Often reading them enriches and freshens my
heterocyclic synthesis idea, and I am ready to use them in my own design and synthesis of the
desired target compounds needed.
My study and research have focused on structure - based drug design or lead optimization by
using crystal protein structure data for years. I am very familiar with protein structures ( α-helix, β -
strand, and loops), and routinely use molecular models to build and analyze ligand-receptor
interactions on the pinpoint atom to atom interaction level. As an example, I have built the HIV
integrase binding site (the amino acids which interact with inhibitors were found from literature)
using chemical models. In such three-dimensional environment inhibitors were designed based
on the binding site orientation and individual amino acid projected side-chains in space for the
best hydrogen bindings, hydrophobic interactions, and ionic interactions. I know this is a faster
and more reliable method to identify new leads, or optimize the existing leads by elaborating their
structures for better potency, selectivity, and pharmacokinetics / pharmacological properties
without jeopardizing their original potency. I am also designing antitumer molecules which target
at cell signalling processes, angiogenesis and telomerase. These molecules bind preferentially or
exclusively on tumor cells.
I have a good knowledge on how to optimize hit/lead: (a) using any available X-ray structure
information of the target binding site to change ring or substituted groups of the hit for the most
favorable binding with receptor; (b) identifying structure activity relationship (SAR) to address lead
optimization, potency, selectivity, and pharmacokinetics. The SAR strategies include hit/lead's
molecular structural variations in (a) homologous series (monoalkylated, cyclopolymethylenic
(b) isosteric replacements ( -Cl to -CF3, -O-to -S-, -NH-, -CH2-, -CH=), ring equivalent exchange;
(c) ring system can be expanded, contracted non-cyclic part can be cyclized to introduce
conformational restriction into the ligand for a higher potency and better bioavailability…
It is quite clear for me to understand the drug’s fate in living organisms, i. e. the drugs orally
administered has to be absorbed by pass through membranes, distributed via the circulation to
the different parts of the body, including desired effect sites (receptor), kidneys where they are
excreted unchanged into urine, or the liver where they are excreted unchanged into the bile or
metabolized and excreted via phase 1 and phase 2 reactions. This knowledge leads me to
design efficient drug molecules based on the ADME considerations.
On the designing safer drug aspect, I know what kinds of chemical structures should be avoided
which may be biotransformed into reactive intermediates (radicals, carbenium ions, nitrenium
ions…) to react with cellular components (proteins, nucleic acids…) leading to organ necrosis.
I am familiar with almost all kinds of organic reactions, e.g. formation of C-C and C-N bonds by
organometallic reagents, or by base- & acid catalyzed reactions, pericyclic reactions, electrophilic
& nucleophilic aromatic substitutions, or organotransition metal assisted reactions, especially
using organoborane reagents. I am also familiar with organic synthesis design by disconnection
approach from target molecules to break them down by a series of disconnections into possible
starting materials.
My experimental abilities include: (a) the skills to carry out air sensitive reactions, especially
getting pure, normally unstable intermediates at low temperature; (b) using NMR, TLC and MS to
monitor reaction progress and optimize reaction conditions; (c) isolating/ purifying desired
products by column chromatography, crystallization or solvent trituration; (d) determination of
chemical structures of complex molecules by NMR, MS, and IR; (e) always seriously thinking lab
safety issues: how to set up reaction safely, any potential problem of the reagents used (toxicity,
instability, flammability …), sudden heating generation in work-up process, any possibility of
explosion caused by peroxide formed or concentrated in evaporation ...
I always use the Reaxys and SciFinder to find the best known procedures before starting target
molecule synthesis. I am proficient in using Chemdraw to write reports and prepare
presentations.
I am educated in computational organic chemistry, biochemistry, molecular virology, and
immunology. All of the knowledge help me to understand how to design/optimize promising
molecules based on the biological mechanism of the diseases and the best interactions between
ligands and binding sites of receptors, which is important for me to work in a multidisciplinary
team together to discover / optimize successful leads efficiently at preclinical phase.
PUBLICATIONS AND PATENTS
1. “Pyrazole Cannabinoids with NO-CB1, NO-CB2 Activitiy”, Jenny Willey, Pinglang Wang, Anu
Mahadevan, Raj K Razdan and Billy R Martin, 19th Annual Symposium of the International
Cannabinoids Research Society, St. Charles, Illinois, USA, July 7-11, 2009
2. "Preparation of tetrahydropyranyl(dichlorophenyl)acetates with high monoamine transporter
affinity", U.S. Pat. Appl. Publ. (2004), US 200414992.
3."Synthesis and Evaluation of Dopamine and Serotonin Transporter Inhibition by Oxacyclic and
Carbacyclic Analogues of Methylphenidate". Peter C. Meltzer, Pinglang Wang, Paul Blundell, and
Bertha K. Madras. J. Medicinal Chemistry, 2003, Vol. 146, No.8, 1538-1545.
4.Asymmetric Hydroboration of Prochiral Olefins with B-2- and -4-isocaranylboranes", Pinglang
Wang, P. V. Ramachandran and Herbert C. Brown. I orally presented on the on the 30th great
lake regional ACS meeting at Chicago in May 30, 1997.
5. " Fatty Acid Oxidation with Sodium Hypochlorite Monitored by NMR". Pinglang Wang and
Bernard Y. Tao. J. of American Oil Chemist Society, 1998, 75(1), 9-14.
6." Syntheis of Cellulose-Fatty Acid Esters for Use as Biodegradable Plastics". Pinglang Wang
and Bernard Y. Tao. J. Environ Polym. Degrad., 1995, 3(2), 115-119.
7." Anti-HIV and Anti-HCMV Activities of New Aurintricarboxylic Acid Analogues". Mark Cushman
and Pinglang Wang. Antiviral Chemistry & Chemotherrapy, 1995, 6(3), 179-186.
8. " Synthesis and Characterization of Long-Chain Fatty Acid Cellulose Ester". Pinglang Wang
and Bernard Y. Tao. J. of Applied Polymer Science, 1994, 52, 755-761.
9. "Structural Investigation and Anti-HIV Activities of High Molecular ATA Polymers". Mark
Cushman, Pinglang Wang, Joseph G. Stowell, and Eric De Clereq. J. Org. Chem. 1992, 57,
7241-7248.
10." Isolation and Structure Elucidation of Low Molecular Weight Components of
Aurintricarboxylic Acids (ATA)". Pinglang Wang, John Kozlowski, and Mark Cushman. J. Org.
Chem., 1992, 57, 3861-3866.
11. "Preparation and Anti-HIV Activity of ATA Fraction and Analog: Direct Correlation of Antiviral
Potency with Molecular Weight". M. Cushman, P. Wang, C. Wild, E.De Clercq, D Schols, M.
Goldman, and J. A. Bowen. J. Med. Chem., 1991, 34, 329-337.
References
Contact this candidate